Conditions: Adenocarcinoma of the Lung Non-small Cell Lung Cancer
Keywords: Adenocarcinoma of the Lung Non-small Cell Lung Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 38
Healthy volunteers: no

Brief summary:
Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of Hsp90 inhibitor AUY922 when given together with erlotinib hydrochloride and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer.

Detailed description:
This is a phase I, dose-escalation study of Hsp90 inhibitor AUY922 followed by a phase II study. Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.

Arms:
arm 1: Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Interventions: intervention 1: erlotinib hydrochloride intervention 2: Hsp90 inhibitor AUY922 intervention 3: laboratory biomarker analysis intervention 4: needle biopsy intervention 5: mutation analysis intervention 6: pharmacological study
Intervention descriptions: intervention 1: Given orally intervention 2: Given IV intervention 3: Correlative studies intervention 4: Undergo image-guided needle biopsy (correlative studies) intervention 5: Correlative studies intervention 6: Correlative studies

Protocol document: